日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Cost-effectiveness of ticagrelor plus aspirin versus aspirin in acute ischaemic stroke or transient ischaemic attack: an economic evaluation of the THALES trial

替格瑞洛联合阿司匹林与单用阿司匹林治疗急性缺血性卒中或短暂性脑缺血发作的成本效益分析：THALES试验的经济学评价

期刊:BMJ Neurology Open
影响因子:2.4
doi:10.1136/bmjno-2023-000478
Tank, Amarjeet; Johnston, S Claiborne; Jain, Ritika; Amarenco, Pierre; Mellström, Carl; Rikner, Klas; Denison, Hans; Ladenvall, Per; Knutsson, Mikael; Himmelmann, Anders; Evans, Scott R; James, Stefan; Molina, Carlos A; Wang, Yongjun; Ouwens, Mario
神经科学
发表日期：2023
文献求助 收藏

Dapagliflozin vs non-SGLT-2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE-TIMI 58 trial: A nationwide observational study

与非SGLT-2抑制剂治疗相比，达格列净治疗可降低2型糖尿病患者的医疗保健成本，这与DECLARE-TIMI 58试验参与者的结果相似：一项全国性观察性研究

期刊:Diabetes Obesity & Metabolism
影响因子:5.7
doi:10.1111/dom.13852
Norhammar, Anna; Bodegard, Johan; Nyström, Thomas; Thuresson, Marcus; Rikner, Klas; Nathanson, David; Eriksson, Jan W
糖尿病
TIM
代谢
发表日期：2019
文献求助 收藏

Specific inhibition of bile acid transport alters plasma lipids and GLP-1

特异性抑制胆汁酸转运会改变血浆脂质和 GLP-1 水平。

期刊:BMC Cardiovascular Disorders
影响因子:2.3
doi:10.1186/s12872-015-0070-9
Rudling, Mats; Camilleri, Michael; Graffner, Hans; Holst, Jens Juul; Rikner, Leif
GLP-1
发表日期：2015
文献求助 收藏

Corrigendum: Prescription of and Adherence to Non-Steroidal Anti-Inflammatory Drugs and Gastroprotective Agents in At-Risk Gastrointestinal Patients

更正：高危胃肠道患者的非甾体类抗炎药和胃保护剂的处方及依从性

期刊:American Journal of Gastroenterology
影响因子:7.6
doi:10.1038/ajg.2016.186
Shaheen, Nicholas J; Falk, Gary W; Iyer, Prasad G; Gerson, Lauren B; Chey, William D; Camilleri, Michael; Chang, Lin; Rikner, Leif; Graffner, Hans; Theocharidou, Eleni; Pieri, Giulia; Mohammad, Ali Omar; Cheung, Michelle; Cholongitas, Evangelos; Banwari, Agarwal; Burroughs, Andrew K; Lanas, Angel; Polo-Tomás, Mónica; Roncales, Pilar; Gonzalez, Miguel A; Zapardiel, Javier
发表日期：2012
文献求助 收藏

A randomized placebo-controlled phase IIb trial of a3309, a bile acid transporter inhibitor, for chronic idiopathic constipation

一项针对慢性特发性便秘的随机安慰剂对照 IIb 期试验，研究了胆汁酸转运体抑制剂 a3309 的疗效。

期刊:American Journal of Gastroenterology
影响因子:7.6
doi:10.1038/ajg.2011.162
Chey, William D; Camilleri, Michael; Chang, Lin; Rikner, Leif; Graffner, Hans
发表日期：2011
文献求助 收藏